Does gefitinib shorten lung cancer survival? Chaos redux

Journal of Clinical Oncology

Volumn 26, Issue 15, 2008, Pages 2428-2430

  Keedy, Vicki L ^a   Arteaga, Carlos L ^a   Johnson, David H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; PLACEBO; QUINAZOLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

APOPTOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL TRIAL; EDITORIAL; GENE AMPLIFICATION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; ONCOGENE K RAS; PRIORITY JOURNAL; SURVIVAL TIME; DRUG ANTAGONISM; LUNG TUMOR; MORTALITY; NOTE; SURVIVAL RATE; TIME;

ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TIME FACTORS;

EID: 45149099893     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.0374     Document Type: Editorial

References (26)

1. Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456, 2008
2. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
3. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al: Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18:752-760, 2007
4. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004
5. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 22:785-794, 2004
6. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
7. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007
8. Rodemann HP, Dittmann K, Toulany M: Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 83:781-791, 2007
9. Mehta V: Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63:5-24, 2005
10. Read WL, Mortimer JE, Picus J: Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94:847-853, 2002
11. Takano T, Ohe Y, Kusumoto M, et al: Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45:93-104, 2004
12. Tsuboi M, Le Chevalier T: Interstitial lung disease in patients with nonsmall-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 23:161-170, 2006
13. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
14. Bell DW, Lynch TJ, Haserlat SM, et al: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-8092, 2005
15. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004
16. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
17. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005
18. Massarelli E, Varella-Garcia M, Tang X, et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890-2896, 2007
19. Douillard J-Y, Kim E, Hirsh V, et al: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pretreated with platinum based chemotherapy: A randomized, open-label phase III study (INTEREST). J Thorac Oncol 2:S305, 2007 (suppl)
20. Gandara DR, Gumerlock PH: Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: Case closed or is the jury still out? J Clin Oncol 23:5856-5858, 2005
21. Gandara DR, Davies AM, Gautschi O, et al: Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: Biologic rationale for combination strategies. Clin Lung Cancer 8:S61-S67, 2007 (suppl 2)
22. Arteaga CL, Ramsey TT, Shawver LK, et al: Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem 272:23247-23254, 1997
23. Anido J, Matar P, Albanell J, et al: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9:1274-1283, 2003
24. Lichtner RB, Menrad A, Sommer A, et al: Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 61:5790-5795, 2001
25. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005
26. Fabian MA, Biggs WH 3rd, Treiber DK, et al: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336, 2005